20/20 Gene Systems
Research, 9430 Key West Ave, Rockville, Maryland, 20850, United States, 11-50 Employees
Phone Number: 24********
Who is 20/20 GENESYSTEMS
20/20 GeneSystems (20/20) was founded in May of 2000 to develop and promote an innovative proteomics product line that provides drug companies, biodefense specialists and life scientists ...
Read More
- Headquarters: 9430 Key West Ave, Rockville, Maryland, 20850, United States
- Date Founded: 2000
- Employees: 11-50
- Revenue: $1 Million to $5 Million
- Active Tech Stack: See technologies
Does something look wrong? Fix it. | View contact records from 20/20 GENESYSTEMS
20/20 GeneSystems Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding 20::20 GeneSystems
Answer: 20/20 GeneSystems's headquarters are located at 9430 Key West Ave, Rockville, Maryland, 20850, United States
Answer: 20/20 GeneSystems's phone number is 24********
Answer: 20/20 GeneSystems's official website is https://2020gene.com
Answer: 20/20 GeneSystems's revenue is $1 Million to $5 Million
Answer: 20/20 GeneSystems's SIC: 8071
Answer: 20/20 GeneSystems's NAICS: 621511
Answer: 20/20 GeneSystems has 11-50 employees
Answer: 20/20 GeneSystems is in Research
Answer: 20/20 GeneSystems contact info: Phone number: 24******** Website: https://2020gene.com
Answer: 20/20 GeneSystems (20/20) was founded in May of 2000 to develop and promote an innovative proteomics product line that provides drug companies, biodefense specialists and life scientists with new tools for protein analysis. Our headquarters are in the heart of the biotechnology corridor in Rockville, Maryland in close proximity to the National Institutes of Health with which we have extensive collaborations. 20/20 GeneSystems develops and commercializes innovative, proprietary diagnostics tests that aid in the fight against cancer. These tests generally fall into two categories: Personalized Medicine: Our patented platform technology for measuring biomarkers in tumors is highly unique in that it combines the visual advantages of classical pathology with the multiplex capabilities needed as a result of genomics and proteomics. This technology is now being used to develop tests to predict responses to several new targeted therapies for kidney and lung cancer. Early detection of lung cancer: 20/20 is developing a blood test for the early detection of lung cancer. This product will be used for screening smokers and former smokers to pre-select or enrich the patient population to receive annual CT scanning long before the disease becomes symptomatic. Biological Detection: 20/20 is on the leading edge of developing technologies to help in the detection of biological toxins.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Sign in to CIENCE GO Data to uncover contact details
Free credits every month